摘要
目的:探讨舒血宁注射液对急性脑梗死患者(ACI)血清血管内皮生长因子(VEGF)、血浆血管性血友病因子(vWF)和基质金属蛋白酶-9(MMP-9)的影响。方法:80例ACI患者随机分为观察组和对照组各40例。两组均采用常规基础治疗,对照组采用依达拉奉30 mg,iv gtt,bid;观察组采用舒血宁注射液25 mg,iv gtt,qd,疗程均为14 d。于治疗1,7,14 d,采用酶联免疫吸附试验测定血清VEGF,vWF,MMP-9水平;并按卒中量表(NIHSS)对神经功能进行评价。结果:治疗后两组NHISS评分均呈下降趋势,14 d观察组NHISS评分低于对照组(P<0.05);治疗后观察组神经功能评价优于对照组(P<0.05);14 d观察组血清VEGF高于对照组(P<0.05),观察组vWF和MMP-9水平低于对照组(P<0.05,P<0.01)。结论:舒血宁注射液能改善ACI患者神经缺损功能,其作用机制可能与其调节VEGF,vWF,MMP-9水平有关。
Objective： To observe the effects of Shuxuening injection on serum vascular endothelial growth factor （VEGF）, plasma von Willebrand factor （vWF） and matrix metalloproteinase-9 （MMP-9） in patients with acute cerebral infarction （ACI）. Method： Eighty subjects with ACI were randomly divided into observation group （n=40） and control group （n=40）. Both groups were received conventional treatment. The control group was given edaravone 30 mg ivgtt, bid; the observation group was given Shuxuening injection 25 mL ivgtt. qd, all for 14 days. The level of VEGF, vWF and MMP-9 were observed by enzyme-linked immunosorbent assay （ELISA） and neurologic function was evaluated. Result： The post-treatment NHISS scores of both groups showed a declining curve, the NHISS score of the observation group at 14 day was lower than that in the control group （P〈0.05）. The post-treatment neurological function evaluation of the observation group was superior to the control group （P〈0.05）. The level of serum VEGF of the observation group at 14 day was higher than the control group （P〈0.05）, the level of vWF and MMP-9 in the observation group was lower than those in the control group （P〈0.05, P〈0.01）. Conclusion： Shuxuening injection can improve neurologic impairment of patients with ACI, the mechanism may be related to the levels of VEGF, vWF and MMP-9.
出处
《中国实验方剂学杂志》
CAS
北大核心
2013年第10期343-345,共3页
Chinese Journal of Experimental Traditional Medical Formulae
